Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of VTX002 in Moderately to Severely Active Ulcerative Colitis
2021-003050-23Phase 2Active
- Sponsor
- Ventyx Biosciences
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing VTX002 with Placebo (2 arms). Primary endpoint: Clinical remission at Week 13 (modified Mayo score). Started Aug 2021; status: active.
02
Drugs
tamuzimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2021-003050-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003050-23.